Citations

Clear

29 citation(s) found for "Shah, Raj N".

Incidence of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), infections and cardiovascular events between chimeric antigen receptor (CAR) T-cell therapy products in multiple myeloma (MM): A nationwide analys
Mahadevia, Himil, Modi, Karnav, Shah, Raj, Modi, Shivani, Vojjala, Nikhil, Vodnala, Deepthi, Khumri, Taiyeb, Cossor, Furha, Mahadevia, Himil , Modi, Karnav, Shah, Raj, Modi, Shivani, Vojjala, Nikhil, Vodnala, Deepthi, Khumri, Taiyeb, Cossor, Furha

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 6351-6351

10.1182/blood-2025-6351 Get It

Abstract Introduction: CAR T-cell therapy represents a pivotal treatment for individuals with relapsed or refractory (R/R) MM. Currently, two CAR T-cell therapeutics have received regulatory approval: Abecma (idecabtagene vicleucel, ide-cel) and Carvykti (ciltacabtagene autoleucel, cilta-cel). Although direct comparative investigations delineating the efficacy of these modalities are absent, clinical trials have shown significant disparities in response and remission rates between these therapies. Both agents are implicated in the manifestation of CRS and ICANS; however, variations in the frequency and severity of these adverse effects have been observed. We harnessed data from the National Inpatient Sample (NIS) to gain a deeper understanding of the incidence of different adverse events associated with both CAR T products in MM. Method: In this retrospective study, the 2022 NIS database was used to identify hospitalizations with MM and those who received ide-cel or cilta-cel using appropriate ICD-10-CM diagnostic and ICD-10-PCS procedure codes. Data on CRS, ICANS, infections, and adverse cardiac events were extracted using relevant ICD-10-CM codes. These outcomes were compared between the two CAR-T products using Pearson's chi-square analysis. Multivariate logistic regression was also performed, adjusting for demographics, hospital-specific characteristics, and comorbidities. Results: We identified 805 patients with MM who received CAR T-cell therapy, among whom 530 patients (60.4% male; 67% Caucasian, 14.6% African American and 17.5% other ethnicities) received ide-cel and 275 patients (70.9% male; 79.6% Caucasian, 14.3% African American and 6.1% other ethnicities) received cilta-cel. The incidence of CRS was 72.6% for ide-cel and 56.4% for cilta-cel, and the difference was almost statistically significant by chi-square analysis (p = 0.051). This difference was not statistically significant after multivariate analysis [Adjusted Odds ratio (OR) = 0.5, CI 0.2 to 1.3, p=0.154]. The incidence of ICANS was 19.8% for ide-cel and 18.2% for cilta-cel, and it was not statistically significant by chi-square analysis (p = 0.825). Among cardiovascular events, there was no significant difference in the incidence of cardiogenic shock (ide-cel vs cilta-cel, 0.9% vs 0%, p = 0.497), stroke (0.9% vs 1.8%, p = 0.661) and arrhythmias (22.6% vs 21.8%, p = 0.892) between these CAR T-cell therapies. Furthermore, there were no significant differences in the incidence of infectious complications, including pneumonia (1.9% vs 0%, p = 0.334), sepsis (0.9% vs 3.6%, p = 0.247), or septic shock (0.9% vs 0%, p = 0.430) between these CAR T-cell therapies. There was no significant difference in all-cause in-hospital mortality between these therapies (1.9% vs 5.5%, p = 0.181). Conclusion: There was no significant difference in the occurrence of CRS and ICANS between ide-cel and cilta-cel in our study. Both CAR T-cell therapies have the potential to cause infections and cardiovascular issues, necessitating careful monitoring, early detection, and timely treatment. When choosing between these CAR T-cell therapies, several factors should be considered, including the patient's previous treatment history, manufacturing time, cost, availability, and potential short-term and long-term side effects. Our study has some limitations, including its retrospective design, dependence on ICD-10 codes for identifying patients with adverse events, and the lack of long-term longitudinal data on adverse effects. However, this study provides important insights for hematologists regarding the rates of specific adverse events associated with both the CAR T-cell products in a real-world setting.
Real-world comparison of thrombotic events in patients with Myelodysplastic Syndromes treated with luspatercept versus erythropoietin-stimulating agents using trinetx database
Gillani, Syed A , Shah, Raj, Agrawal, Shubham , Singh, Vijendra K. , Vojjala, Nikhil , Gillani, Syed Fahad, Mahadevia, Himil , Vegivinti, Charan Thej Reddy , Singh, Vijendra

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 22-22

10.1182/blood-2025-22 Get It

Abstract Background: Luspatercept, an erythroid maturation agent, has shown efficacy in improving anemia in both β-thalassemia and lower-risk myelodysplastic syndromes (MDS). In the BELIEVE trial, which led to its approval in transfusion-dependent β-thalassemia, thromboembolic events were notably higher in patients with risk factors such as splenectomy. More recently, the COMMANDS trial demonstrated superior transfusion independence with luspatercept over erythropoiesis-stimulating agents (ESAs) in ESA-naive, lower-risk MDS patients. However, limited data exist regarding comparative thrombotic risk in real-world MDS populations. We conducted a multicenter, real-world study to evaluate thrombotic event rates associated with luspatercept versus ESAs in MDS patients without prior venous thromboembolism (VTE). Methods: We queried the TriNetX Research Network, a federated real-time electronic health record (EHR) database covering over 100 million patients across major healthcare organizations. Adults (≥18 years) with a diagnosis of MDS (ICD-10-CM code D46) and no prior history of deep vein thrombosis (DVT) or pulmonary embolism (PE) were included. Patients were stratified based on treatment with luspatercept or ESAs (epoetin alfa or darbepoetin alfa). Propensity score matching (PSM) using a 1:1 nearest-neighbor algorithm without replacement was performed to balance demographics and clinical covariates. Primary outcomes included the incidence of DVT, PE, and composite VTE events within 12 months of therapy initiation. Results: A total of 6,448 patients with MDS and no prior VTE were identified: 5,698 received ESAs and 750 received luspatercept. The overall mean age was 72.5 ± 13.5 years, with 48.1% male. After PSM, 741 patients were included in each treatment arm. The matched cohort had a mean age of 76.7 ± 10.7 years, and 41.3% were female. In the ESA group, 58/741 (7.8%) developed DVT compared to 27/741 (3.6%) in the luspatercept group (Hazard Ratio [HR] 1.4; 95% CI, 0.9–2.3). PE occurred in 27 ESA-treated patients (3.6%) versus 13 luspatercept-treated patients (1.8%) (HR 1.3; 95% CI, 0.6–2.7; p=0.941). The overall composite VTE rate was 10.0% (74/741) in the ESA group and 4.9% (36/741) in the luspatercept group (HR 1.3; 95% CI, 0.9–2.0; p=0.732). Conclusion: In this large, multicenter real-world analysis, we observed a numerically lower incidence of thrombotic events with luspatercept compared to erythropoietin-based agents in patients with MDS, though differences did not reach statistical significance. These findings support the thrombotic safety profile of luspatercept observed in clinical trials and warrant further prospective validation.
Incidence of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), infections and cardiovascular events across different chimeric antigen receptor (CAR) T-cell therapy products in large B-cell lymphoma (DLBCL): A
Mahadevia, Himil , Modi, Karnav , Shah, Raj, Modi, Shivani , Khumri, Taiyeb, Vodnala, Deepthi, Cossor, Furha, Vojjala, Nikhil

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 8012-8012

10.1182/blood-2025-8012 Get It

Abstract Introduction: CAR T-cell therapy is an important treatment option for patients with relapsed or refractory (R/R) DLBCL. Three CAR T-cell products have received approval: axicabtagene ciloleucel (Yescarta), lisocabtagene maraleucel (Breyanzi), and tisagenlecleucel (Kymriah). Although direct head-to-head studies comparing the three therapies do not exist, clinical trials have revealed notable differences in response rates and remission rates among them. All three products induce CRS and ICANS; however, variations in the incidence and severity of these adverse effects have been observed. We utilized data from the National Inpatient Sample (NIS) to gain further insights into the incidence of various adverse events associated with different CAR-T products in DLBCL. Method: In this retrospective study, the 2022 NIS database was used to identify hospitalizations with DLBCL and those who received Yescarta, Breyanzi, or Kymriah using appropriate ICD-10-CM diagnostic and ICD-10-PCS procedure codes. Data on CRS, ICANS, infections, and adverse cardiac events were extracted using relevant ICD-10-CM codes. These outcomes were compared across different CAR-T products using Pearson's chi-square analysis. Multivariate logistic regression was also performed, adjusting for demographics, hospital-specific characteristics, and comorbidities. Results: We identified 1440 patients with DLBCL. Among these, 1100 patients (64.6% male; 70.7% Caucasian, 8.8% African American, 20.5% other ethnicities) received Yescarta, 90 patients (66.7% male; 82.4% Caucasian, 0% African American, 17.7% other ethnicities) received Kymriah and 250 patients (64% male; 82.6% Caucasian, 10.9% African American, 6.5% other ethnicities) received Breyanzi. The incidence of CRS was 52% for Breyanzi, 44.4% for Kymriah and 68.6% for Yescarta, and the difference was statistically significant by chi-square analysis (p = 0.03). This difference remained statistically significant for Kymriah after multivariate analysis [Adjusted Odds ratio (OR) = 0.3, CI 0.1 to 0.9, p=0.032], but not for Breyanzi (Adjusted OR = 0.3, CI 0.1 to 0.9, p=0.032) in comparison to Yescarta. The incidence of ICANS was 16% for Breyanzi, 22.2% for Kymriah, and 33.2% for Yescarta, with a statistically significant difference observed by chi-square analysis (p = 0.05). This difference remained statistically significant for Breyanzi after multivariate analysis [Adjusted OR = 0.3, CI 0.1 to 0.6, p=0.002], but not for Kymriah (Adjusted OR = 0.6, CI 0.1 to 2.9, p=0.551) in comparison to Yescarta. Among cardiovascular events, there was no significant difference in the incidence of acute myocardial infarction (Yescarta vs Kymriah vs Breyanzi, 0.5% vs 0% vs 0.2%, p = 0.487), stroke (0.5% vs 5.6% vs 2%, p = 0.07), cardiogenic shock (0.5% vs 0% vs 0%, p = 0.880), and arrhythmias (20.9% vs 27.8% vs 32%, p = 0.258) among these CAR T-cell therapies. Furthermore, there were no significant differences in the incidence of infectious complications, including pneumonia (5.9% vs 5.6% vs 2%, p = 0.510), sepsis (5% vs 5.6% vs 6%, p = 0.962), or septic shock (2.3% vs 0% vs 0%, p = 0.535) among these CAR T-cell therapies. There was no difference in all-cause in-hospital mortality across these therapies (2.3% vs 5.6% vs 2%, p = 0.692). Conclusion: Kymriah showed lower CRS rates and Breyanzi showed lower ICANS rates in comparison to Yescarta in our study. All CAR T-cell therapies have the potential to cause infections and cardiac events, which require monitoring, early identification and prompt treatment. When selecting among various CAR T-cell products, several factors must be considered, including the patient's lymphoma type, prior treatment history, manufacturing turnaround time, cost, availability, and potential short-term and long-term side effects. The limitations of our study include its retrospective nature, reliance on ICD-10 codes to identify patients with adverse events, and the absence of longitudinal data on long-term adverse events. Nevertheless, this study provides essential insights for hematologists regarding the incidence of specific adverse events associated with different CAR T-cell products within the real-world population.
Incidence and outcomes of Clostridioides difficile infection in BCMA and CD19 CAR-T cell therapy.
Shah, Raj, Tom, Fady El, Mahadevia, Himil, Vojjala, Nikhil, Kassem, Jad, Patel, Kalan, Shah, Raj, Tom, Fady El, Mahadevia, Himil, Vojjala, Nikhil, Kassem, Jad, Patel, Kalan

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 7678-7678

10.1182/blood-2025-7678 Get It

Abstract Background: Clostridioidesdifficile infection (CDI) represents a significant infectious complication in both Chimeric Antigen Receptor(CAR) T-cell therapy and hematopoietic stem cell transplant (HSCT) recipients. We sought to investigate the incidence and outcomesof CDI among various CAR-T therapy products. Methods: This retrospective study used the 2022 National Inpatient Sample Database to identify and include adult patients with a primary diagnosis of four hematologic malignancies (Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM), Acute Lymphoblastic Leukemia (ALL), and Acute Myeloid Leukemia (AML). In this cohort, we isolated patients who developed CDI using ICD-10 codes. Subgroup analysis was performed based on the type of CAR-T cell therapy and HSCT recipients. Multivariate regression analysis was performed to identify independent risk factors for CDI and mortality. A p-value < 0.05 was considered statistically significant. Results: A total of 8,739 patients with CDI were identified among 507,559 patients with four hematologic malignancies, representing an overall incidence of 1.72%. Patients receiving CAR-T cell therapy (5% vs 2%, p<0.05), bone marrow transplant (BMT, 3% vs 2%, p<0.05), and those with a history of BMT (6% vs 2%, p<0.05) were at significantly higher risk for CDI. Among individual CAR-T products, the incidence was: for CD19-directed CAR-T, Brexu-cel 5%, Axi-cel 6%, Tisa-cel 5%, and Liso-cel 3%; for BCMA-directed CAR-T, Ide-cel 4% and Cilta-cel 5%. There was no significant difference in CDI rates between these individual CAR-T products. Among CAR-T recipients by cancer type, CDI incidence was NHL 5%, MM 4%, ALL 7%, and AML 5% (p=0.79). Multivariate regression identified history of HSCT (OR 2.11, 95% CI 1.09–4.08), cytokine release syndrome (OR 1.7; 1.26–2.52), protein-energy malnutrition (OR 2.08; 1.83–2.36), graft versus host disease (OR 2.52; 2.02–3.15), and female sex (OR 1.23; 1.10–1.38) as significant independent risk factors for CDI (all p<0.05). Overall mortality in those with CDI was 6% compared to 5% without, and mortality increased substantially to 36% in those requiring surgical intervention for CDI. Conclusion: In patients with hematologic malignancies, identifying risk factors and rates of CDI in CAR-T cell therapy is essential for prompt recognition and effective management. Future research on optimizing CDI screening protocol and prevention strategies can help reduce mortality and morbidity in this immunocompromised population.
Incidence of infections, cardiac events, neurological toxicity and cytokine response syndrome (CRS) in patients treated with chimeric antigen receptor (CAR) T cell therapy: A 3-year nationwide analysis.
Mahadevia, Himil , Modi, Karnav , Shah, Raj, Modi, Shivani , Batra, Nitya, Arya, Yajur , Syal, Arshi , Shah, Kashish, Savani, Saloni , Chaudhari, Jahnavi, Vodnala, Deepthi, Khumri, Taiyeb, Cossor, Furha, Sharma, Parth , Peshin, Supriya , Jain, Akhil , Gupta, Kush , Ponvilawan, Ben

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 7018-7018

10.1200/jco.2025.43.16_suppl.7018 Get It

7018 Background: CAR-T cell therapy represents a notable advancement in treating relapsed/refractory (R/R) hematological malignancies. Adverse events include CRS, infections, and neurological and cardiac complications. While there are reports from major academic institutions on the adverse effects of CAR-T therapy, we used data from the National Inpatient Sample (NIS) to gather national estimates of complications related to CAR-T therapy. Methods: A retrospective study was conducted to analyze patients who underwent CAR-T cell therapy by utilizing appropriate ICD-10-PCS procedure codes (XW033C3, XW043C3, XW23346, XW24346, XW23376, and XW24376) from NIS 2019 to 2021. Data regarding infections, toxic encephalopathy (a surrogate for neurological toxicity), and adverse cardiac events were extracted using relevant ICD-10-CM diagnostic codes. Patients experiencing various grades of CRS were identified through specific ICD-10 codes available in 2021 (Grades 1-5: D89.831-D89.835). Results: This study analyzed 6515 patients who underwent CAR-T cell therapy from January 2019 to December 2021. Among them, 60.7% were male. 74.6% were Caucasian, 11.7% were Asian and 6.7% were African American. 49.8% of patients had private insurance, 36.2% had Medicare, and 8.6% had Medicaid. 6.8% of patients were diagnosed with pneumonia, while sepsis occurred in 7.4% of patients and 3% experienced septic shock. 19.4% of patients experienced cardiac arrhythmias, and major cardiovascular events were recorded in 4.7% of the cohort. Acute myocardial infarction and stroke were documented in 0.6 and 1.2% of patients, respectively. Toxic encephalopathy was reported in 19.7% of patients. Among 2235 patients identified to have received CAR-T in 2021, 59.7% developed CRS. Grade 1 and grade 2 CRS were reported in 32% and 21% of patients, respectively, while grade 3 and grade 4 reactions were noted in 4.7% and 2% of patients, with no cases of grade 5 identified. The mean total cost of hospitalization was 308,364$, and the mean length of hospital stay was 19.5 days. The overall in-hospital mortality rate was 3.4%. Conclusions: Our study describes real-world outcomes from a large dataset of CAR-T patients. Infections pose a significant challenge with CAR-T therapy, highlighting the importance of early detection and timely antimicrobial treatment. CRS is common, with a 60% incidence, similar to previous clinical trials (55%). Immediate management is crucial for addressing CRS toxicity. Adverse neurological and cardiovascular incidents are often reported, emphasizing the need for meticulous monitoring and coordinating multidisciplinary care plans. The financial burdens also bear mentioning: CAR-T therapy costs significantly higher than autologous stem cell transplants. Further studies to address these issues are warranted.
The Success and Safety of Endoscopic Retrograde Cholangiopancreatography in Surgically Altered Gastrointestinal Anatomy
Han, Samuel , Edmundowicz, Steven A. , Attwell, Augustin , Hammad, Hazem, Wani, Sachin , Edmundowicz, Steven A , Kolb, Jennifer M. , Shah, Raj J.

Mayo Clinic

Medical Sciences | February 11, 2025 | Volume: 13 | Issue: 1 | Pages: 18

10.3390/medsci13010018 | PMID 39982243 Get It

Background/Objectives: Performing endoscopic retrograde cholangiopancreatography (ERCP) in surgically altered gastrointestinal anatomy remains challenging, frequently necessitating the use of forward-viewing endoscopes. Given the challenge in endoscope selection based on the type of altered anatomy, the aim of this study was to examine ERCP success rates by specific endoscopes for different anatomy types. Methods: This single-center retrospective study examined ERCPs performed in patients with surgically altered gastrointestinal anatomy during an 18-year period. Enteroscopy success, cannulation success, and intervention success rates were compared between the different anatomy and endoscope types. Results: This study included a total of 334 adult patients (665 total ERCPs) with altered anatomy. The pediatric colonoscope was most frequently utilized (32.2%), and the majority of procedures were performed for biliary indications. Enteroscopy success was 82.2% in Roux-en-Y gastric bypass (RYGB), 97% in Billroth II, 91.5% in Whipple, and 93.2% in Roux-en-Y hepaticojejunostomy (RYHJ). Cannulation success was 90.5% in RYGB, 90.5% in Billroth II, 83.6% in Whipple, and 90.6% in RYHJ. Intervention success was 88.2% in Billroth II, 65.1% in RYGB, 81.6% in Whipple, and 87.5% in RYHJ. In patients with RYGB and RYHJ, SBE was utilized most frequently, with rotational enteroscopy having the highest success rates. The overall adverse event rate was 5.1%, with the majority of these being mild in severity. Conclusions: This large retrospective study found ERCP with forward-viewing endoscopes to be safe and effective for a variety of surgically altered anatomy types. Despite recent advances seen with endoscopic ultrasound-guided drainage procedures, this study advocates for ERCP as the initial approach for pancreaticobiliary access in surgically altered anatomy.
Technical Factors Associated With the Benefit of Prophylactic Pancreatic Stent Placement During High-Risk Endoscopic Retrograde Cholangiopancreatography: A Secondary Analysis of the SVI Trial Data Set
Elmunzer, B. Joseph , Zhang, Jingwen , Coté, Gregory A. , Wani, Sachin , Shah, Raj J. , Bang, Ji Young , Varadarajulu, Shyam , Singh, Vikesh K. , Khashab, Mouen A. , Kwon, Richard S. , Scheiman, James M., Keilin, Steven , Chak, Amitabh , Slivka, Adam, Mullady, Daniel , Kushnir, Vladimir , Buxbaum, James , Keswani, Rajesh N. , Gardner, Timothy B. , Forbes, Nauzer , Rastogi, Amit, Ross, Andrew S., Law, Joanna K. , Chen, Yen‐I , Smith, Zachary L. , Petersen, Bret T. , Wang, Andrew Y. , Saltzman, John R. , Spitzer, Rebecca L., Ordiah, Collins, Spino, Cathie , Foster, Lydia D. , Durkalski‐Mauldin, Valerie, Group*, on behalf of the SVI Study, Shah, Raj , Singh, Vikesh K , Kwon, Richard S , Willingham, Field F , Chak, Amitabh , Mullady, Daniel , Forbes, Nauzer , Ross, Andrew , Law, Joanna , Chen, Yen-I , Smith, Zachary L , Serrano, Jose , Petersen, Bret, Wang, Andrew Y , Saltzman, John R , Spino, Cathie , Foster, Lydia D , Edmundowicz, Steven A. , Willingham, Field F. , Papachristou, Georgios I. , Yachimski, Patrick , Barkun, Alan , Serrano, José , Group*, on behalf of the SVI Study

Mayo Clinic

American Journal of Gastroenterology | August 27, 2024 | Volume: 120 | Issue: 4 | Pages: 811-815

10.14309/ajg.0000000000003052 | PMID 39207308 Get It

INTRODUCTION: Prophylactic pancreatic stent placement (PSP) is effective for preventing pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP) in high-risk cases, but the optimal technical approach to this intervention remains uncertain. METHODS: In this secondary analysis of 787 clinical trial patients who underwent successful stent placement, we studied the impact of (i) whether pancreatic wire access was achieved for the sole purpose of PSP or naturally during the conduct of the case, (ii) the amount of effort expended on PSP, (iii) stent length, (iv) stent diameter, and (v) guidewire caliber. We used logistic regression models to examine the adjusted association between each technical factor and post-ERCP pancreatitis (PEP). RESULTS: Ninety-one of the 787 patients experienced PEP. There was no clear association between PEP and whether pancreatic wire access was achieved for the sole purpose of PSP (vs occurring naturally; odds ratio [OR] 0.82, 95% confidence interval [CI] 0.37–1.84), whether substantial effort expended on stent placement (vs nonsubstantial effort; OR 1.58, 95% CI 0.73–3.45), stent length (>5 vs ≤5 cm; OR 1.01, 95% CI 0.63–1.61), stent diameter (≥5 vs <5 Fr; OR 1.13, 95% CI 0.65–1.96), or guidewire caliber (0.035 vs 0.025 in; 0.83, 95% CI 0.49–1.41). DISCUSSION: The 5 modifiable technical factors studied in this secondary analysis of large-scale randomized trial data did not appear to have a strong impact on the benefit of prophylactic PSP in preventing PEP after high-risk ERCP. Within the limitations of post hoc subgroup analysis, these findings may have important implications in procedural decision making and suggest that the benefit of PSP is robust to variations in technical approach.
A Protocol for the Inclusion of Minoritized Persons in Alzheimer Disease Research From the ADNI3 Diversity Taskforce
Okonkwo, Ozioma C. , Ashford, Miriam T. , Conti, Catherine , Strong, Joe, Raman, Rema , Nosheny, Rachel L. , Flenniken, Derek , Miller, Melanie J. , Diaz, Adam , Soto, Annabelle M., Ances, Beau M. , Beigi, Maryam , Doraiswamy, P. Murali , Duara, Ranjan , Farlow, Martin R. , Grossman, Hillel, Mintzer, Jacobo , Reist, Christopher , Rogalskı, Emily , Sabbagh, Marwan N. , Salloway, Stephen, Schneider, Lon S. , Petersen, Ronald C. , Aisen, Paul , Weiner, Michael W., Initiative, Alzheimer’s Disease Neuroimaging, Ances, Beau M , Mindt, Mónica Rivera , Donohue, Michael , Duara, Ranjan , Shah, Raj C. , Initiative, Alzheimer’s Disease Neuroimaging

Mayo Clinic

JAMA Network Open | August 9, 2024 | Volume: 7 | Issue: 8 | Pages: e2427073

10.1001/jamanetworkopen.2024.27073 | PMID 39120898 Get It

ImportanceBlack or African American (hereinafter, Black) and Hispanic or Latino/a/x (hereinafter, Latinx) adults are disproportionally affected by Alzheimer disease, but most research studies do not enroll adequate numbers of both of these populations. The Alzheimer’s Disease Neuroimaging Initiative-3 (ADNI3) launched a diversity taskforce to pilot a multipronged effort to increase the study inclusion of Black and Latinx older adults.ObjectiveTo describe and evaluate the culturally informed and community-engaged inclusion efforts to increase the screening and enrollment of Black and Latinx older adults in ADNI3.Design, Setting, and ParticipantsThis cross-sectional study used baseline data from a longitudinal, multisite, observational study conducted from January 15, 2021, to July 12, 2022, with no follow-up. The study was conducted at 13 ADNI3 sites in the US. Participants included individuals aged 55 to 90 years without cognitive impairment and those with mild cognitive impairment or Alzheimer disease.ExposuresEfforts included (1) launch of an external advisory board, (2) changes to the study protocol, (3) updates to the digital prescreener, (4) selection and deployment of 13 community-engaged research study sites, (5) development and deployment of local and centralized outreach efforts, and (6) development of a community-science partnership board.Main Outcomes and MeasuresScreening and enrollment numbers from centralized and local outreach efforts, digital advertisement metrics, and digital prescreener completion.ResultsA total of 91 participants enrolled in the trial via centralized and local outreach efforts, of which 22 (24.2%) identified as Latinx and 55 (60.4%) identified as Black (median [IQR] age, 65.6 [IQR, 61.5-72.5] years; 62 women [68.1%]). This represented a 267.6% increase in the monthly rate of enrollment (before: 1.11 per month; during: 4.08 per month) of underrepresented populations. For the centralized effort, social media advertisements were run between June 1, 2021, and July 31, 2022, which resulted in 2079 completed digital prescreeners, of which 1289 met criteria for subsequent site-level screening. Local efforts were run between June 1, 2021, to July 31, 2022. A total of 151 participants underwent site-level screening (100 from local efforts, 41 from centralized efforts, 10 from other sources).Conclusions and RelevanceIn this cross-sectional study of pilot inclusion efforts, a culturally informed, community-engaged approach increased the inclusion of Black and Latinx participants in an Alzheimer disease cohort study.
Etiology of White Matter Hyperintensities in Autosomal Dominant and Sporadic Alzheimer Disease
Shirzadi, Zahra , Schultz, Stephanie A. , Yau, Wai‐Ying Wendy , Fitzpatrick, Colleen , Levin, Raina, Kantarci, Kejal , Preboske, Gregory M., Jack, Clifford R. , Farlow, Martin R. , Hassenstab, Jason , Morris, John C. , Xiong, Chengjie , Levey, Allan I. , Gordon, Brian A. , Salloway, Stephen , Perrin, Richard J. , Xiong, Chengjie , Fox, Nick C. , Goate, Alison , Day, Gregory S. , Chui, Helena C., Berman, Sarah , Mori, Hiroshi , Ruthirakuhan, Myuri , Wu, Che‐Yuan , Sohrabi, Hamid R. , Martins, Ralph N. , Johnson, Keith A. , Greenberg, Steven M. , Chhatwal, Jasmeer P. , Initiative, Dominantly Inherited Alzheimer Network and the Alzheimer’s Disease Neuroimaging, Weiner, Michael W. , Aisen, Paul, Petersen, Ronald , Jack, Clifford R., Jagust, William J. , Trojanowki, John Q., Morris, John C., Shaw, Leslie M. , Khachaturian, Zaven S., Carrillo, Maria, Potter, William Z., Bernard, Marie , Jackson, Jonathan , Masliah, Eliezer , Masterman, Donna, Okonkwo, Ozioma C. , Ryan, Laurie, Silverberg, Nina, Fleisher, Adam , Sacrey, Diana Truran, Fockler, Juliet , Conti, Cat, Jin, Chengshi , Nosheny, Rachel L. , Ashford, Miriam T. , Flenniken, Derek , Kormos, Adrienne, Montine, Tom, Raman, Rema , Jiménez, Gustavo , Gessert, Devon, Salazar, Jennifer, Zimmerman, Caileigh, Cabrera, Yuliana, Walter, Sarah , Miller, Garrett, Coker, Godfrey, Clanton, Taylor, Hergesheimer, Lindsey, Adegoke, Olusegun, Mahboubi, Payam, Moore, Shelley, Pizzola, Jeremy, Shaffer, Elizabeth , Sloan, Brittany, Forghanian-Arani, Arvin, Borowski, Bret, Ward, Chad, Gunter, Jeff, Jahanshad, Neda , DeCarli, Charles, Knaack, Alexander , Chen, Stephanie Rossi, Choe, Mark, Crawford, Karen , Reiman, Eric M. , Mathis, Chet, Landau, Susan, Cairns, Nigel J., Householder, Erin, Franklin, Erin , Bernhardt, Haley, Taylor‐Reinwald, Lisa, Korecka, Magdalena , Figurski, Michael, Neu, Scott, Apostolova, Liana G. , Foroud, Tatiana M., Faber, Kelley, Wilmes, Kristi, Thal, Leon J., Lind, Betty, Crissey, Rachel, Carter, Raina, Dolen, Sara, Schneider, Lon S. , Pawluczyk, Sonia, Becerra, Mauricio, Teodoro, Liberty, Dagerman, Karen, Spann, Bryan M., Brewer, James B., Vanderswag, Helen, Ziolkowski, Jaimie, Heidebrink, Judith L. , Zbizek-Nulph, Lisa, Mason, Sara S., Albers, Colleen S., Johnson, Kris , Villaneuva-Meyer, Javier, Pavlik, Valory , Pacini, Nathaniel, Lamb, Ashley, Kass, Joseph S. , Doody, Rachelle S., Shibley, Victoria, Chowdhury, Munir , Rountree, Susan, Dang, Mimi, Mintz, Akiva , Winkfield, David, Carroll, Maria , Stobbs-Cucchi, Georgia , Oliver, Angela , Creech, Mary L., Mintun, Mark A., Schneider, Stacy, Geldmacher, David , Love, Marissa Natelson , Griffith, Randall, Clark, David, Brockington, John, Marson, Daniel , Grossman, Hillel, Goldstein, Martin , Mitsis, Effie, Samuels, Patricia, Duara, Ranjan , Greig‐Custo, Maria T., Rodriguez, Rosemarie, Albert, Marilyn, Onyike, Chiadi, Farrington, Leonie, Rudow, Scott, Brichko, Rottislav, Kielb, Stephanie , Smith, Amanda , Raj, Balebail Ashok, Fargher, Kristin, Shulman, Melanie , Faustin, Arline , Rao, Julia, Castro, Karen M. , Ulysse, Anaztasia, Chen, Shannon, Sheikh, Mohammed O., Singleton-Garvin, Jamika, Doraiswamy, P. Murali , Petrella, Jeffrey R. , James, Olga, Borges‐Neto, Salvador , Karlawish, Jason , Vaishnavi, Sanjeev , Clark, Christopher M. , Arnold, Steven E. , Smith, Charles D. , Khouli, Riham El , Raslau, Flavius D., Oakley, MaryAnn, Simpson, Donna M., Martin, Kim, Kowalski, Nancy, Keltz, Melanie, Goldstein, Bonnie S., Makino, Kelly M., Ismail, M. Saleem , Brand, Connie, Thai, Gaby , Pierce, Aimee, Witbracht, Megan , Mathews, Dana, Quiceno, Mary , Hajjar, Ihab , Cellar, Janet S., Swerdlow, Russell H. , Kremen, Sarah , Tingus, Kathleen, Lu, Po H. , Bartzokis, George, Woo, Ellen, Graff‐Radford, Neill R. , Parfitt, Francine, Poki-Walker, Kim, Hake, Ann Marie , Matthews, Brandy R., Herring, Scott, Dyck, Christopher H. van , Mecca, Adam P. , Good, Susan P., MacAvoy, Martha G., Carson, Richard E. , Varma, Pradeep, Chertkow, Howard , Vaitekunis, Susan, Hosein, Chris, Mudge, Benita, Assaly, Michele, Rachinsky, Irina, Kertesz, Andrew, Drost, Dick, Rogers, John, Grant, Ian , Muse, Brittanie, Rogalskı, Emily , Robson, Jordan, Mesulam, M.‐Marsel, Kerwin, Diana , Wu, Chuang‐Kuo, Johnson, Nancy E., Lipowski, Kristine, Weıntraub, Sandra , Bonakdarpour, Borna , Hernando, Raymundo, Sarrael, Antero, Rosen, Howard J., Johnson, Kathleen, Reynolds, Brigid, Poe, Jessica, Sperling, Reisa A., Marshall, Gad A. , Yesavage, Jerome A. , Taylor, Joy L. , Chao, Steven, Coleman, Jaila, White, Jessica D. , Lane, Barton , Rosen, Allyson , Tinklenberg, Jared, Belden, Christine M. , Clark, Kelly, Zamrini, Edward , Sabbagh, Marwan, Kowall, Neil W. , Budson, Andrew E. , Ntekim, Oyonumo, Wolday, Saba, Khan, Javed , Nwulia, Evaristus , Nadarajah, Sheeba , Lerner, Alan J. , Ogrocki, Paula, Tatsuoka, Curtis , Fatica, Parianne, Olichney, John , Bates, Vernice, Capote, Horacio, Rainka, Michelle, Borrie, Michael, Lee, T‐Y, Asthana, Sanjay , Carlsson, Cynthia M., Perrin, Allison, Burke, Anna , Kataki, Maria , Hart, David , Zimmerman, Earl A. , Celmins, Dzintra, Smith, Karen Ekstam, Shim, Hyungsub , Nam, Ki Won , Schtulz, Susan K., Williamson, Jeff D. , Craft, Suzanne , Cleveland, Jo, Ott, Brian R. , Drake, Jonathan, Tremont, Geoffrey , Daiello, Lori A. , Ritter, Aaron, Bernick, Charles , Munic, Donna, O’Connell, Abigail, Mintzer, Jacobo , Wiliams, Arthur, Masdeu, Joseph C. , Shi, Jiong , Garcia, Angelica, Newhouse, Paul , Salloway, Steven, Malloy, Paul, Correia, Stephen , Kittur, Smita, Blank, Karen, Anderson, Karen, Flashman, Laura A. , Seltzer, Marc, Hynes, Mary L. , Santulli, Robert B. , Relkin, Norman , Chiang, Gloria, Lee, Athena, Lin, Michael, Ravdin, Lisa , Sood, Ajay, Blanchard, Kimberly S., Fleischman, Debra , Varon, Daniel, Greig, Maria T., Martin, Kimberly S., Reist, Christopher , Sadowsky, Carl, Villena, Teresa, Rosen, Howard, Peskind, Elaine R. , Li, Gail, Vöglein, Jonathan , Méndez, Patricio Chrem, Ikonomović, Snežana, Nadkarni, Neelesh K. , Ramírez, Laura, Leon, Yudy Milena, Ramos, Cláudia , Alzate, Diana, Baena, Ana , Londono, Natalia, Laske, Christoph , Kuder-Buletta, Elke, Gräber‐Sultan, Susanne, Preische, Oliver, Hofmann, Anna, Ishii, Kenji , Senda, Michio , Riddle, Meghan C., Menard, William, Bodge, Courtney, Surti, Mustafa, Sanchez-Gonzalez, VJ, Orozco-Barajas, Maribel, Esposito, Bianca, Fernanadez, Victoria, Jerome, Gina, Herries, Elizabeth, Seyfried, Nicholas T. , Bechara, Jacob , Chen, Allison , Hantler, Nancy, Hornbeck, Russ C. , Jarman, Steve, Keefe, Sarah , Koudelis, Deborah, Massoumzadeh, Parinaz , Nicklaus, Joyce , Pulizos, Christine, Mishall, Sheetal, Sabaredzovic, Edita, Deng, Emily , Candela, Madison, Smith, Hunter , Scott, Jalen , Gremminger, Emily, Ma, Yinjiao , Bui, Ryan , Lu, Ruijin , Daniels, Alisha , Courtney, Laura, Supnet, Charlene , Xu, Jinbin , Ringman, John M. , Barthélemy, Nicolas R. , Jack, Clifford R , Gordon, Brian A , Kantarci, Kejal , Day, Gregory S , Vöglein, Jonathan , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Goate, Alison M , Supnet-Bell, Charlene , Berman, Sarah , Levey, Allan I , Kremen, Sarah , Joseph‐Mathurin, Nelly , Jucker, Mathias , Xiong, Chengjie , Karch, Celeste M. , Schofield, Peter R. , McDade, Eric , Cruchaga, Carlos , Allegri, Ricardo , Koeppe, Robert A. , Chui, Helena C. , Sánchez‐Valle, Raquel , Lee, Jae‐Hong , Rosa-Neto, Pedro , Swardfager, Walter , Benzinger, Tammie L.S. , Bateman, Randall J. , Sperling, Reisa Anne , Schultz, Aaron P. , Initiative, Dominantly Inherited Alzheimer Network and the Alzheimer’s Disease Neuroimaging, Jack, Clifford R., Toga, Arthur W. , Beckett, Laurel , Green, Robert C. , Saykin, Andrew J. , Morris, John C., Barnes, Lisa L. , González, Hector, Ho, Carole , Hsiao, John , Veitch, Dallas P. , Neuhaus, John M , Rafii, Michael S. , Donohue, Michael , Smith, Stephanie R. , Harvey, Danielle , Arani, Arvin , Schwarz, Christopher G. , Jones, David T. , Senjem, Matthew L. , Vemuri, Prashanthi , Reid, Robert I. , Malone, Ian B. , Thompson, Paul M. , Thomopoulos, Sophia I. , Nir, Talia M. , Fletcher, Evan M. , Tosun, Duygu , Yushkevich, Paul A. , Das, Sandhitsu R. , Chen, Kewei , Mathis, Chet, Nho, Kwangsik T. , Risacher, Shannon L. , Shen, Li , Nudelman, Kelly , Silbert, Lisa C. , Kaye, Jeffrey , Carter, Raina, Quinn, Joseph F. , Lord, Joanne L. , Knopman, David S. , Stern, Yaakov , Honig, Lawrence S. , Ances, Beau M. , Goldstein, Martin A., Greenberg, Jonathan, Shah, Raj C. , Lamar, Melissa , Duara, Ranjan , Sadowski, Martin , Wısnıewskı, Thomas , Wong, Terence Z. , Wolk, David A. , Jicha, Gregory A. , López, Oscar L. , Porsteinsson, Anton P. , Yanez, Beatriz, Sosa, Elizabeth M. , Kelley, Brendan , Nguyen, Trung Dung , Womack, Kyle , Lah, James J. , Burns, Jeffrey M. , Brooks, William Miles , Silverman, Daniel H.S. , Teng, Edmond , Brosch, Jared R. , Black, Sandra E. , Stefanovic, Bojana , Heyn, Chris , Hsiung, Ging‐Yuek Robin , Kim, Ellen , Sossi, Vesna , Feldman, Howard , Finger, Elizabeth C. , Pasternak, Stephen , Miller, Bruce L. , Perry, David C. , Turner, Raymond Scott , MCCann, Kelly, Sperling, Reisa A., Atri, Alireza , Killiany, Ronald , Stern, Robert A. , Mez, Jesse , Obisesan, Thomas O. , Maillard, Pauline , Carmichael, Owen , Bartha, Robert , Johnson, Sterling C. , Carlsson, Cynthia M. , Scharre, Douglas W. , Tarawneh, Rawan M. , Miller, Del D. , Ponto, Laura L. Boles , Koleva, Hristina , Yang, Mia , Sink, Kaycee M. , Masdeu, Joseph C , Potkin, Steven G. , Salloway, Steve , Pearlson, Godfrey D. , Sood, Ajay, Arfanakis, Konstantinos , Varón, Daniel , Martínez, Walter Fabián , Petrie, Eric C. , Noble, James M. , Surace, Ezequiel , Lopera, Francisco Javier , Aguillon, David , Londono, Natalia, Moreno, Sonia, Ikeuchi, Takeshi , Kasuga, Kensaku , Niimi, Yoshiki , Cash, David M. , Roh, Jee Hoon , Takada, Leonel Tadao , Renton, Alan , Marsh, Jacob A. , Llibre‐Guerra, Jorge J. , Johnson, Erik C. B. , Brooks, William S. , Chen, Charles , Flores, Shaney , McCullough, Austin , McKay, Nicole S. , Wáng, Qīng , Candela, Madison, Hobbs, Diana A. , Wang, Peter , Xu, Xiong, Li, Yan , Sosa, Ana Luisa , Smith, Jennifer A.

Mayo Clinic

JAMA Neurology | October 16, 2023 | Volume: 80 | Issue: 12 | Pages: 1353

10.1001/jamaneurol.2023.3618 | PMID 37843849 Get It

ImportanceIncreased white matter hyperintensity (WMH) volume is a common magnetic resonance imaging (MRI) finding in both autosomal dominant Alzheimer disease (ADAD) and late-onset Alzheimer disease (LOAD), but it remains unclear whether increased WMH along the AD continuum is reflective of AD-intrinsic processes or secondary to elevated systemic vascular risk factors.ObjectiveTo estimate the associations of neurodegeneration and parenchymal and vessel amyloidosis with WMH accumulation and investigate whether systemic vascular risk is associated with WMH beyond these AD-intrinsic processes.Design, Setting, and ParticipantsThis cohort study used data from 3 longitudinal cohort studies conducted in tertiary and community-based medical centers—the Dominantly Inherited Alzheimer Network (DIAN; February 2010 to March 2020), the Alzheimer’s Disease Neuroimaging Initiative (ADNI; July 2007 to September 2021), and the Harvard Aging Brain Study (HABS; September 2010 to December 2019).Main Outcome and MeasuresThe main outcomes were the independent associations of neurodegeneration (decreases in gray matter volume), parenchymal amyloidosis (assessed by amyloid positron emission tomography), and vessel amyloidosis (evidenced by cerebral microbleeds [CMBs]) with cross-sectional and longitudinal WMH.ResultsData from 3960 MRI sessions among 1141 participants were included: 252 pathogenic variant carriers from DIAN (mean [SD] age, 38.4 [11.2] years; 137 [54%] female), 571 older adults from ADNI (mean [SD] age, 72.8 [7.3] years; 274 [48%] female), and 318 older adults from HABS (mean [SD] age, 72.4 [7.6] years; 194 [61%] female). Longitudinal increases in WMH volume were greater in individuals with CMBs compared with those without (DIAN: t = 3.2 [P = .001]; ADNI: t = 2.7 [P = .008]), associated with longitudinal decreases in gray matter volume (DIAN: t = −3.1 [P = .002]; ADNI: t = −5.6 [P &amp;lt; .001]; HABS: t = −2.2 [P = .03]), greater in older individuals (DIAN: t = 6.8 [P &amp;lt; .001]; ADNI: t = 9.1 [P &amp;lt; .001]; HABS: t = 5.4 [P &amp;lt; .001]), and not associated with systemic vascular risk (DIAN: t = 0.7 [P = .40]; ADNI: t = 0.6 [P = .50]; HABS: t = 1.8 [P = .06]) in individuals with ADAD and LOAD after accounting for age, gray matter volume, CMB presence, and amyloid burden. In older adults without CMBs at baseline, greater WMH volume was associated with CMB development during longitudinal follow-up (Cox proportional hazards regression model hazard ratio, 2.63; 95% CI, 1.72-4.03; P &amp;lt; .001).Conclusions and RelevanceThe findings suggest that increased WMH volume in AD is associated with neurodegeneration and parenchymal and vessel amyloidosis but not with elevated systemic vascular risk. Additionally, increased WMH volume may represent an early sign of vessel amyloidosis preceding the emergence of CMBs.
Pragmatic evaluation of events and benefits of lipid lowering in older adults ( PREVENTABLE ): Trial design and rationale
Joseph, Jacob , Pajewski, Nicholas M. , Dolor, Rowena J , Sellers, Mary Ann, Perdue, Letitia , Peeples, Sheronda R., Henrie, Adam M., Woolard, Nancy , Benziger, Catherine P. , Mixon, Amanda S. , VanWormer, Jeffrey J. , Chatterjee, Ranee , Newby, L. Kristin , Cicek, Mine , Williams, Neely , Decker, Jake E., Ou, Jiafu , Choudhary, Gaurav , Gazmuri, Raúl J. , Schmader, Kenneth E. , Vaughan, Camille P. , Ambrosius, Walter T. , Williamson, Jeff D. , Johnson, Kimberly S. , Espinoza, Sara , Markland, Alayne D. , Bazzano, Lydia , Benziger, Catherine P , Shapiro, Michael D , Kistler, Christine E , Gill, Thomas M , Newby, L Kristin , Cicek, Mine S , Ou, Jiafu , Gazmuri, Raúl J , Vaughan, Camille P , Supiano, Mark A , Shah, Raj C , Alexander, Karen P , Pajewski, Nicholas M , Espinoza, Sara , Jones, W. Schuyler , Orkaby, Ariela R. , Shapiro, Michael D. , Polonsky, Tamar S. , Chamberlain, Alanna M. , Forman, Daniel E. , Knowlton, Kirk U. , Gill, Thomas M. , Hammill, Bradley G. , Rubinstein, Jack , Roumie, Christianne L. , Effron, Mark B , Cooper‐DeHoff, Rhonda M. , Supiano, Mark A. , Shah, Raj C. , Whittle, Jeff , Hernandez, Adrian F. , Alexander, Karen P.

Mayo Clinic

Journal of the American Geriatrics Society | April 21, 2023 | Volume: 71 | Issue: 6 | Pages: 1701-1713

10.1111/jgs.18312 | PMID 37082807 Get It

Abstract Whether initiation of statins could increase survival free of dementia and disability in adults aged ≥75 years is unknown. PREVENTABLE, a double‐blind, placebo‐controlled randomized pragmatic clinical trial, will compare high‐intensity statin therapy (atorvastatin 40 mg) with placebo in 20,000 community‐dwelling adults aged ≥75 years without cardiovascular disease, disability, or dementia at baseline. Exclusion criteria include statin use in the prior year or for >5 years and inability to take a statin. Potential participants are identified using computable phenotypes derived from the electronic health record and local referrals from the community. Participants will undergo baseline cognitive testing, with physical testing and a blinded lipid panel if feasible. Cognitive testing and disability screening will be conducted annually. Multiple data sources will be queried for cardiovascular events, dementia, and disability; survival is site‐reported and supplemented by a National Death Index search. The primary outcome is survival free of new dementia or persisting disability. Co‐secondary outcomes are a composite of cardiovascular death, hospitalization for unstable angina or myocardial infarction, heart failure, stroke, or coronary revascularization; and a composite of mild cognitive impairment or dementia. Ancillary studies will offer mechanistic insights into the effects of statins on key outcomes. Biorepository samples are obtained and stored for future study. These results will inform the benefit of statins for increasing survival free of dementia and disability among older adults. This is a pioneering pragmatic study testing important questions with low participant burden to align with the needs of the growing population of older adults.